# Intranasal Insulin in Frontotemporal Dementia (FTD)

> **NCT04115384** · PHASE2 · TERMINATED · sponsor: **HealthPartners Institute** · enrollment: 3 (actual)

## Conditions studied

- Frontotemporal Dementia, Behavioral Variant

## Interventions

- **DRUG:** Novolin-R insulin

## Key facts

- **NCT ID:** NCT04115384
- **Lead sponsor:** HealthPartners Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-09
- **Primary completion:** 2020-02-26
- **Final completion:** 2023-05-15
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** COVID - unable to restart after restrictions were lifted
- **Last updated:** 2023-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04115384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04115384, "Intranasal Insulin in Frontotemporal Dementia (FTD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04115384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*